These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8056703)

  • 1. In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
    Pérez-Giraldo C; Rodríguez-Benito A; Morán FJ; Hurtado C; Blanco MT; Gómez-García AC
    J Antimicrob Chemother; 1994 Apr; 33(4):845-8. PubMed ID: 8056703
    [No Abstract]   [Full Text] [Related]  

  • 2. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
    Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of five quinolones against Chlamydia pneumoniae.
    Hammerschlag MR; Hyman CL; Roblin PM
    Antimicrob Agents Chemother; 1992 Mar; 36(3):682-3. PubMed ID: 1320366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between biofilms formed by Staphylococcus epidermidis and quinolones.
    Yassien M; Khardori N
    Diagn Microbiol Infect Dis; 2001 Jul; 40(3):79-89. PubMed ID: 11502373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
    Schumacher-Perdreau F; Peters G
    Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
    Prenna M; Montanari MP; Mingoia M; Biavasco F; Ripa S; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):816-9. PubMed ID: 9923533
    [No Abstract]   [Full Text] [Related]  

  • 11. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
    Rastogi N; Goh KS
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phagocytosis and killing of slime-producing Staphylococcus epidermidis bypolymorphonuclear leukocytes. Effects of sparfloxacin.
    Morán FJ; García C; Pérez-Giraldo C; Hurtado C; Blanco MT; Gómez-García AC
    Rev Esp Quimioter; 1998 Mar; 11(1):52-7. PubMed ID: 9795290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1991 Nov; 28(5):695-9. PubMed ID: 1663929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters.
    Pascual A; García I; Ramirez de Arellano E; Perea EJ
    J Antimicrob Chemother; 1995 Aug; 36(2):425-30. PubMed ID: 8522473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):168-71. PubMed ID: 2060518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
    Barry AL; Pfaller MA; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):243-6. PubMed ID: 1317799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of new quinolones against coryneform bacteria.
    Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
    J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.